222 related articles for article (PubMed ID: 17014384)
1. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
[TBL] [Abstract][Full Text] [Related]
2. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
Endocrinology; 2007 Jun; 148(6):2778-87. PubMed ID: 17379647
[TBL] [Abstract][Full Text] [Related]
5. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
6. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
[TBL] [Abstract][Full Text] [Related]
7. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
Ominsky MS; Li X; Asuncion FJ; Barrero M; Warmington KS; Dwyer D; Stolina M; Geng Z; Grisanti M; Tan HL; Corbin T; McCabe J; Simonet WS; Ke HZ; Kostenuik PJ
J Bone Miner Res; 2008 May; 23(5):672-82. PubMed ID: 18433301
[TBL] [Abstract][Full Text] [Related]
8. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
9. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
10. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
11. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats.
Valenta A; Roschger P; Fratzl-Zelman N; Kostenuik PJ; Dunstan CR; Fratzl P; Klaushofer K
Bone; 2005 Jul; 37(1):87-95. PubMed ID: 15869920
[TBL] [Abstract][Full Text] [Related]
13. Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.
Shen V; Birchman R; Liang XG; Wu DD; Dempster DW; Lindsay R
J Bone Miner Res; 1998 May; 13(5):883-90. PubMed ID: 9610753
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
15. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
[TBL] [Abstract][Full Text] [Related]
16. The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat.
Campbell GM; Bernhardt R; Scharnweber D; Boyd SK
Bone; 2011 Aug; 49(2):225-32. PubMed ID: 21515436
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
19. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats.
Fuchs RK; Shea M; Durski SL; Winters-Stone KM; Widrick J; Snow CM
Bone; 2007 Aug; 41(2):290-6. PubMed ID: 17544352
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]